Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)
Close on Nov 17, 2026Market cap $13.19MP/E –Yield –
Lipocine pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lipocine's pe ratio was 11.5× on Jan 31, 2023.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 11.5× | +2.9 |
| 2022 | Dec 30, 2022 | 8.6× | – |
See a number that looks wrong?